US Patent

US7399865 — Protein tyrosine kinase enzyme inhibitors

Composition of Matter · Assigned to Wyeth LLC · Expires 2030-12-29 · 5y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of a specific chemical structure, as described in the specification, which are protein tyrosine kinase enzyme inhibitors.

USPTO Abstract

This invention provides compounds of formula 1, having the structure wherein R 1 , R 2 , R 3 , R 4 , and R 5 are described within the specification.

Drugs covered by this patent

Patent Metadata

Patent number
US7399865
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-12-29
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.